/
RPRX
$58.60+$0.04 (+0.07%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$26.4B
445M shares
52-week range
$34.08 – $60.44
93% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change+$20.35
Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
www.royaltypharma.com- Employees
- 100
- IPO / List date
- Jun 16, 2020
- HQ
- NEW YORK, NY
Held by traders on TradeandTell
No one on the platform currently holds RPRX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 790,937 | $37.9M |
Insider activity (SEC Form 4)
Dividend history
TTM yield · 1.58% ($0.92/share)
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-08-14 | $0.2350 | 2026-09-10 |
| 2026-05-15 | $0.2350 | 2026-06-10 |
| 2026-02-20 | $0.2350 | 2026-03-10 |
| 2025-11-14 | $0.2200 | 2025-12-10 |
| 2025-08-15 | $0.2200 | 2025-09-10 |
| 2025-05-16 | $0.2200 | 2025-06-10 |
| 2025-02-21 | $0.2200 | 2025-03-10 |
| 2024-11-15 | $0.2100 | 2024-12-10 |
| 2024-08-16 | $0.2100 | 2024-09-13 |
| 2024-05-16 | $0.2100 | 2024-06-14 |
Recent trades on TradeandTell
No one on the platform has traded RPRX yet.
